Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorUniversity Hospital, Basel, Switzerland
About this trial
The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.
Eligibility criteria
Qualifiers
Adult healthy controls
No medication (including hormonal contraception)
Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months
Confirmed diagnosis of AVP-Deficiency
Disqualifiers
Participation in a trial with investigational drugs within 30 days
BMI >30
Age >50
Illicit substance use (except for cannabis) during the last 30 days
Trial design
Treatments tested in this trial
- estradiol valerate
- esthinylestradiol
Treatment groups
28 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov